Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01351480 · ClinicalTrials.gov registry record · Phase 3
Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients
A Phase 3 study of Rheumatoid Arthritis, sponsored by Arthritis & Rheumatic Disease Specialties Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT01351480 is a Phase 3 study of Rheumatoid Arthritis that has completed, run by Arthritis & Rheumatic Disease Specialties Research. The registered enrollment target is 34 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01351480, a Phase 3 study of Rheumatoid Arthritis, has completed, sponsored by Arthritis & Rheumatic Disease Specialties Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if the use of sub-cutaneous (SC) abatacept provides any structural benefit in patients with rheumatoid arthritis who have failed prior use of TNF therapy.
Conditions Studied
Interventions
- BIOLOGICAL abatacept
Study Locations (1)
Florida
- Arthritis & Rheumatic Disease Specialties Research - Aventura
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2011-06 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01351480
The ClinicalTrials.gov registry entry for NCT01351480 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The listed sponsor is Arthritis & Rheumatic Disease Specialties Research, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which abatacept is the first listed.
NCT01351480 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT01351480 about?
NCT01351480 is a clinical study titled "Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients". The purpose of this study is to determine if the use of sub-cutaneous (SC) abatacept provides any structural benefit in patients with rheumatoid arthritis who have failed prior use of TNF therapy.
What is the current status of trial NCT01351480?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 34 participants. The study started on 2011-06. Estimated completion is 2014-04.
What conditions does trial NCT01351480 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT01351480?
The interventions under investigation include: abatacept (BIOLOGICAL).
Who is sponsoring clinical trial NCT01351480?
This trial is sponsored by Arthritis & Rheumatic Disease Specialties Research, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01351480 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
RECRUITING · Phase 3
-
Ra-pro Pragmatic Trial
RECRUITING · Phase 3
-
Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
-
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.